MannKind gets FDA approval for AFREZZA for treatment diabetes
The inhalation powder in AFREZZA is delivered using a small, discreet and easy-to-use inhaler. The company said that the AFREZZA should be administered at the start of a
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.
TAS-102 achieved statistically significant improvements in overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC) whose disease had progressed after or who